Mankind Pharma Signs Licensing Pact with Innovent for Sintilimab

Mankind Pharma news today

Mankind Pharma has announced a licensing agreement with Chinese pharmaceutical giant Innovent Biologics to introduce Sintilimab, a cutting-edge PD-1 immunotherapy, in India. The partnership grants Mankind exclusive rights to register, import, market, sell, and distribute the drug, while Innovent oversees manufacturing and supply. This development signifies Mankind’s strategic focus on strengthening its oncology portfolio in the ₹8,000-crore Indian oncology market.

Key Takeaways

Drug Name: Sintilimab (Marketed as TYVYT in China).

Mechanism: Blocks PD-1/PD-L1 pathway to enhance T-cell activity against cancer cells.

Launch Timeline: Expected in three years post Phase III trials and regulatory approvals.

Market Size: Indian oncology market valued at ₹8,000 crore.

Mankind Pharma Share Price: Stable amid announcement.

Sintilimab Overview

Sintilimab, developed by Innovent Biologics in collaboration with Eli Lilly, is a monoclonal antibody targeting multiple cancer types. It is approved for eight indications in China, including:

Cancer Type	Indications
Non-Small Cell Lung Cancer	First-Line Treatment
Liver Cancer	Advanced Stages
Gastric Cancer	First-Line Therapy
Esophageal Cancer	Recurrence or Advanced Cases
Endometrial Cancer	Advanced Stages
Hodgkin’s Lymphoma	Second-Line Therapy

Strategic Importance for Mankind Pharma

Mankind’s entry into oncology began in 2023 with the acquisition of Panacea Biotec for ₹1,872 crore. The addition of Sintilimab aligns with the company's focus on biologics and immunotherapies as future cancer treatments. The drug's competitive pricing is expected to enhance accessibility in the Indian market.

Mankind Pharma Share Price and Market Impact

Mankind Pharma share price remains steady following the announcement, reflecting investor confidence in its strategic expansion. With over 16,000 personnel and 13,000 stockists, Mankind’s robust distribution network is well-positioned to support the launch.

Mankind Pharma’s licensing agreement with Innovent Biologics marks a significant step towards transforming cancer care in India. By introducing Sintilimab, the company is poised to make advanced immunotherapy accessible to Indian patients while solidifying its position in the oncology market.

You can open an account with Bajaj Broking in minutes.

Download the Bajaj Broking app now from Play Store or App Store.